Can CD3 +/HLA-DR + activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?

László Váróczy, L. Gergely, Zsófia Miltényi, M. Aleksza, A. Illés

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response. Both CD4 + helper and CD8 + cytotoxic T-cells bear HLA-DR molecules as important surface activation markers. Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy. Using the methods of immunofluorescence staining and flow cytometry, we found the ratio of CD3 +/HLA-DR + cells significantly higher in NHL patients before treatment compared to healthy controls (10.63% versus 2.97%, P <0.001). During the period of polychemotherapy, this ratio began to increase significantly (10.63% versus 16.94%, P = 0.006). After treatment, the ratio of activated T cells decreased, however, we detected significantly higher rate of CD3 +/HLA-DR + lymphocytes in patients who relapsed within 1 year than in those who stayed in remission (9.55% versus 20.62%, P <0.001). We suppose that investigation of CD3 +/HLA-DR + activated T cells might be a promising method to determine the prognostics of lymphoma patients.

Original languageEnglish
Pages (from-to)155-157
Number of pages3
JournalImmunology Letters
Volume97
Issue number1
DOIs
Publication statusPublished - Feb 15 2005

Fingerprint

HLA-DR Antigens
Non-Hodgkin's Lymphoma
T-Lymphocytes
Combination Drug Therapy
Fluorescent Antibody Technique
Immune System
Lymphoma
Flow Cytometry
Clone Cells
Lymphocytes
Staining and Labeling
Therapeutics

Keywords

  • Activated T cell
  • CD3 /HLA-DR
  • Flow cytometry
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Can CD3 +/HLA-DR + activated T cells predict the prognosis of non-Hodgkin's lymphoma patients? / Váróczy, László; Gergely, L.; Miltényi, Zsófia; Aleksza, M.; Illés, A.

In: Immunology Letters, Vol. 97, No. 1, 15.02.2005, p. 155-157.

Research output: Contribution to journalArticle

@article{c6f571bc36754269a644f724462d8b58,
title = "Can CD3 +/HLA-DR + activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?",
abstract = "The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response. Both CD4 + helper and CD8 + cytotoxic T-cells bear HLA-DR molecules as important surface activation markers. Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy. Using the methods of immunofluorescence staining and flow cytometry, we found the ratio of CD3 +/HLA-DR + cells significantly higher in NHL patients before treatment compared to healthy controls (10.63{\%} versus 2.97{\%}, P <0.001). During the period of polychemotherapy, this ratio began to increase significantly (10.63{\%} versus 16.94{\%}, P = 0.006). After treatment, the ratio of activated T cells decreased, however, we detected significantly higher rate of CD3 +/HLA-DR + lymphocytes in patients who relapsed within 1 year than in those who stayed in remission (9.55{\%} versus 20.62{\%}, P <0.001). We suppose that investigation of CD3 +/HLA-DR + activated T cells might be a promising method to determine the prognostics of lymphoma patients.",
keywords = "Activated T cell, CD3 /HLA-DR, Flow cytometry, Non-Hodgkin's lymphoma",
author = "L{\'a}szl{\'o} V{\'a}r{\'o}czy and L. Gergely and Zs{\'o}fia Milt{\'e}nyi and M. Aleksza and A. Ill{\'e}s",
year = "2005",
month = "2",
day = "15",
doi = "10.1016/j.imlet.2004.10.005",
language = "English",
volume = "97",
pages = "155--157",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Can CD3 +/HLA-DR + activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?

AU - Váróczy, László

AU - Gergely, L.

AU - Miltényi, Zsófia

AU - Aleksza, M.

AU - Illés, A.

PY - 2005/2/15

Y1 - 2005/2/15

N2 - The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response. Both CD4 + helper and CD8 + cytotoxic T-cells bear HLA-DR molecules as important surface activation markers. Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy. Using the methods of immunofluorescence staining and flow cytometry, we found the ratio of CD3 +/HLA-DR + cells significantly higher in NHL patients before treatment compared to healthy controls (10.63% versus 2.97%, P <0.001). During the period of polychemotherapy, this ratio began to increase significantly (10.63% versus 16.94%, P = 0.006). After treatment, the ratio of activated T cells decreased, however, we detected significantly higher rate of CD3 +/HLA-DR + lymphocytes in patients who relapsed within 1 year than in those who stayed in remission (9.55% versus 20.62%, P <0.001). We suppose that investigation of CD3 +/HLA-DR + activated T cells might be a promising method to determine the prognostics of lymphoma patients.

AB - The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response. Both CD4 + helper and CD8 + cytotoxic T-cells bear HLA-DR molecules as important surface activation markers. Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy. Using the methods of immunofluorescence staining and flow cytometry, we found the ratio of CD3 +/HLA-DR + cells significantly higher in NHL patients before treatment compared to healthy controls (10.63% versus 2.97%, P <0.001). During the period of polychemotherapy, this ratio began to increase significantly (10.63% versus 16.94%, P = 0.006). After treatment, the ratio of activated T cells decreased, however, we detected significantly higher rate of CD3 +/HLA-DR + lymphocytes in patients who relapsed within 1 year than in those who stayed in remission (9.55% versus 20.62%, P <0.001). We suppose that investigation of CD3 +/HLA-DR + activated T cells might be a promising method to determine the prognostics of lymphoma patients.

KW - Activated T cell

KW - CD3 /HLA-DR

KW - Flow cytometry

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=11144315982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144315982&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2004.10.005

DO - 10.1016/j.imlet.2004.10.005

M3 - Article

C2 - 15626488

AN - SCOPUS:11144315982

VL - 97

SP - 155

EP - 157

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 1

ER -